Vistagen Therapeutics Bolsa (NASDAQ: VTGN)

Vistagen Therapeutics (NASDAQ:VTGN) Bolsa

Vistagen Therapeutics

VistaGen Therapeutics

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics Inc

News

XCHG Limited's XCharge NA Deploys Two Dual-Dispenser GridLink Chargers At Newly Launched EV Charging Depot In Riverside, California, Developed And Operated By Gateway Fleets

AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) will release earnings results for the fourth quarter, after the <a href="https://www.benzinga.com/quote/AVAV/earnings">closing bell on Tuesday, June 24.</a>
Analysts expect the Arlington, Virginia-based company to report quarterly earnings at $1.42 per share on revenue of $242.69 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 18, AeroVironment and UAS Denmark announced a strategic partnership to advance allied UAS capabilities in Europe.
AeroVironment shares gained 0.8% to close at $191.23 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/avav/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Baird analyst Peter Arment maintained an Outperform rating and raised the price target from $146 to $210 on June 6, 2025. This analyst has an accuracy rate of 84%.</li>
<li>RBC Capital analyst Ken Herbert reinstated an Outperform rating with a price target of $190 on May 12, 2025. This analyst has an accuracy rate of 74%.</li>
<li>BTIG analyst Andre Madrid reiterated a Buy rating with a price target of $245 on Sept. 17, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Raymond James analyst Brian Gesuale downgraded the stock from Outperform to Market Perform on Sept. 17, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Alembic Global analyst Peter Skibitski upgraded the stock from Neutral to Overweight with a price target of $216 on Aug. 28, 2024. This analyst has an accuracy rate of 73%</li>
</ul>
Considering buying AVAV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/avav/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24030520/image-346-1024x574.png" alt="" class="wp-image-959192" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24030520/image-346-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24030520/image-346-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24030520/image-346-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24030520/image-346.png 1145w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Trading Ideas

AVAV

Top Wall Street Forecasters Revamp AeroVironment Expectations Ahead Of Q4 Earnings

Acacia Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) ("Acacia" or the "Company"), which acquires and operates businesses across the industrial, energy and technology sectors, today announced the appointment of Michael Zambito as Chief Financial Officer, effective June 24, 2025. Kirsten Hoover, Acacia's current Interim Chief Financial Officer, will continue to serve as Acacia's Controller and remains a key member of Acacia's finance team.
Prior to joining Acacia, Mr. Zambito spent the past 30 years at Ernst &amp; Young, a multinational professional services firm, and a global leader in assurance, tax, transactions, and consulting services. Most recently, he spent over 23 years, including the last 17 as a Partner, in Ernst &amp; Young's EY-Parthenon (formerly Strategy and Transactions) practice, a market-leading strategy, transactions, and corporate finance provider. Prior to this, he spent seven years in Ernst &amp; Young's NY audit practice, as staff through manager. Mr. Zambito received his MBA from Columbia Business School and holds a Bachelor of Science degree in Business Administration with a major in Accounting from the University of Richmond.

Management

ACTG

Acacia Appoints EY Veteran Michael Zambito as CFO, Former Interim CFO Kirsten Hoover Stays On as Controller

Macro Economic Events

Politics

Global

Economics

General

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Posts On Truth Social: 'IRAN WILL NEVER REBUILD THEIR NUCLEAR FACILITIES!'

OPRX

OptimizeRx Appoints CEO Steve Silvestro To Board Of Directors To Strengthen Leadership And Advance Strategic Growth Plans

President Trump On Truth Social Posts: 'ISRAEL is not going to attack Iran. All planes will turn around and head home, while doing a friendly "Plane Wave" to Iran. Nobody will be hurt, the Ceasefire is in effect! Thank you for your attention to this matter! DONALD J. TRUMP, PRESIDENT OF THE UNITED STATES'

WhatsApp&nbsp;has emerged as a key arena for AI chatbot competition, reportedly posing a potential challenge to&nbsp;Meta Platforms Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) AI dominance.
What Happened: WhatsApp, with over 3 billion global users, has become a prime platform for various AI chatbots, including those from OpenAI and Perplexity, alongside Meta&#8217;s own assistant, <a href="https://www.businessinsider.com/meta-ai-competition-whatsapp-chatbot-battleground-2025-6">reported</a> Business Insider. This intense competition could potentially hinder Meta AI&#8217;s goal of becoming the default choice for its billions of users.
Notably, in the April earnings call, Meta&#8217;s CEO, Mark Zuckerberg, revealed that WhatsApp is &#8220;the&nbsp;largest surface that people use&nbsp;Meta AI on.&#8221;
WhatsApp, a primary battleground for consumer AI, is witnessing a surge in rival chatbots vying for user attention. Despite Meta AI being integrated into WhatsApp, the app&#8217;s strong usage continues.
OpenAI, which brought ChatGPT to WhatsApp last year, is working to make AI more widely accessible. Meanwhile, Perplexity&#8217;s chatbot, launched on WhatsApp this spring, experienced such overwhelming demand at launch that it briefly crashed.
These competing chatbots utilize the WhatsApp Business Platform, allowing them to reach WhatsApp&#8217;s vast global audience without requiring Meta&#8217;s direct approval. This is particularly beneficial in emerging markets&nbsp;such as India and Brazil, where&nbsp;WhatsApp is a primary communication tool.
Meta did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/23/06/33000234/california-democrat-ro-khanna-questions-feds-2-inflation-target-why-is-it-sacrosanct-as-opposed-to-s" target="_blank" rel="noreferrer noopener">Ro Khanna Wants To Know Why Fed's 2% Inflation Target Is &#8216;Sacrosanct&#8217; &#8211; Benzinga</a>
Why It Matters: The rise of AI chatbots on WhatsApp comes at a time when Meta is facing challenges. Just a day before this report,&nbsp;WhatsApp was banned on<a href="https://www.benzinga.com/markets/tech/25/06/46066338/whatsapp-blocked-on-us-house-devices-over-transparency-encryption-concerns-meta-app-deemed-high-risk-while-imessage-facetime-and-teams-get-green-light"> U.S. House</a> devices&nbsp;over transparency and encryption concerns, further complicating Meta&#8217;s position.
However, Meta&#8217;s WhatsApp is not without its potential. An analyst recently estimated that Meta could potentially generate over <a href="https://www.benzinga.com/markets/tech/25/06/45969694/mark-zuckerbergs-meta-could-rake-in-over-10-billion-in-annual-ad-revenue-from-whatsapp-by-2028-says-analyst">$10 billion</a> in annual ad revenue from its&nbsp;WhatsApp messaging service by 2028, indicating that the platform still holds significant value for the company.
Benzinga's Edge Rankings place Meta Platforms in the 85th percentile for momentum and the 28th percentile for value, reflecting its strong performance in both areas. Check the detailed report <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a>.&nbsp;
On a year-to-date basis, Meta stock surged 16.57%, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a>
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46050532/mark-zuckerbergs-maga-pivot-driven-by-elon-musk-envy-image-goals-say-betrayed-meta-insiders-report">Mark Zuckerberg&#8217;s MAGA Pivot Driven By Elon Musk Envy, Image Goals, Say &#8216;Betrayed&#8217; Meta Insiders: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Zuckerberg's AI Dreams Hit WhatsApp Speed Bump As OpenAI, Perplexity Challenge Meta On Its Own Turf: Report

Digital Asset, the developer behind the Canton Network, has raised $135 million in a funding round backed by major Wall Street players <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42047066/goldman-sachs-to-spin-out-digital-assets-platform-amid-blockchain-push">including Goldman Sachs</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and Citadel Securities, alongside leading crypto investors.
The round, led by DRW Venture Capital and Tradeweb Markets, signals growing institutional confidence in blockchain solutions designed for traditional finance.
The new capital will <a href="https://www.prnewswire.com/news-releases/digital-asset-raises-135-million-to-accelerate-adoption-of-canton-network-302488899.html">accelerate</a> the onboarding of real-world assets onto the Canton Network, which Digital Asset describes as the first public, permissionless Layer-1 blockchain offering configurable privacy for institutional use.
The network already supports a broad range of assets, including bonds, commodities, repos, mortgages, and alternative funds.
Other participants in the round include BNP Paribas, Circle Ventures, The Depository Trust &amp; Clearing Corporation (DTCC), IMC, Liberty City Ventures, Optiver, Paxos, Polychain Capital, QCP, Republic Digital, 7RIDGE and Virtu Financial.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46055372/new-crypto-fund-targets-early-builders-is-this-where-the-next-blockchain-unicorn-starts">New Crypto Fund Targets Early Builders: Is This Where The Next Blockchain Unicorn Starts?</a>
Goldman Sachs' Mathew McDermott said, "Our longstanding relationship with Digital Asset stems from a deep conviction in the strength of their technology, which continues to be foundational to the development and ongoing success of GS DAP."
Don Wilson, CEO of DRW, emphasized the maturity of the market, stating, "We are at the inflection point of being able to use blockchain at scale in traditional markets."
The funding is set to bolster Canton&#8217;s position as a blockchain protocol tailored for regulated institutions, offering privacy controls that have long been a barrier to enterprise blockchain adoption. 
Digital Asset says Canton already has nearly 400 participants within its ecosystem, reflecting momentum among both traditional and decentralized finance players.
Digital Asset CEO Yuval Rooz added, "This funding milestone validates the inevitability of what we envisioned years ago: a privacy-enabled public blockchain designed specifically for institutional adoption."
The Canton Network enables asset synchronization across financial markets with an emphasis on real-time, private, and interoperable settlement, a feature that its backers see as a step toward modernizing financial infrastructure.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46053180/sequans-takes-a-page-from-microstrategy-is-bitcoin-the-new-corporate-treasury-play">Sequans Takes A Page From MicroStrategy: Is Bitcoin The New Corporate Treasury Play?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

What's Driving Goldman Sachs And Citadel Into Crypto? The $135M Digital Asset Funding Round Explained

Macquarie analyst Aditya Suresh upgrades MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) from Neutral to Outperform and announces $110 price target.

Upgrades

Analyst Ratings

MMYT

Macquarie Upgrades MakeMyTrip to Outperform, Announces $110 Price Target

Affiliates Of CriticalPoint Acquires Consumer Wearables Brand Pura Vida Bracelets From Vera Bradley For Undisclosed Terms

<ul>
<li>Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock</li>
<li>Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC</li>
</ul>

PSTV

Plus Therapeutics Restructures $15m Equity Financing, Cancels Warrants And Pre-Funded Shares To Simplify Capital Structure

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.87%</li>
<li>Argus Research analyst Gary Hovis downgraded the stock from Buy to Hold on May 27, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Jefferies analyst Julien Dumoulin-Smith downgraded the stock from Hold to Underperform and slashed the price target from $10 to $9 on May 20, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On May 1, AES announced it has reaffirmed 2025 guidance and long-term growth rate targets.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest AES <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624"><img loading="lazy" decoding="async" width="938" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054242/image-351.png" alt="" class="wp-image-959490" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054242/image-351.png 938w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054242/image-351-300x268.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054242/image-351-768x686.png 768w" sizes="(max-width: 938px) 100vw, 938px" /></a></figure>
<h3 class="wp-block-heading">Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.11%</li>
<li>Barclays analyst Nicholas Campanella maintained an Equal-Weight rating and cut the price target from $48 to $45 on April 30, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Wells Fargo analyst Sarah Akers maintained an Equal-Weight and lowered the price target from $46 to $44 on April 28, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On April 25, Portland Gen Electric posted downbeat quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest POR <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624"><img loading="lazy" decoding="async" width="928" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054320/image-352.png" alt="" class="wp-image-959491" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054320/image-352.png 928w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054320/image-352-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054320/image-352-768x697.png 768w" sizes="(max-width: 928px) 100vw, 928px" /></a></figure>
<h3 class="wp-block-heading">Avista Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.13%</li>
<li>Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating and lowered the price target from $40 to $39 on Jan. 28, 2025. This analyst has an accuracy rate of 67%.</li>
<li>B of A Securities analyst Ross Fowler reinstated an Underperform rating with a price target of $37 on Sept. 12, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On June 9, Avista reached all-party, all issues settlement in Idaho general rate cases.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624">AVA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624"><img loading="lazy" decoding="async" width="923" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054357/image-353.png" alt="" class="wp-image-959492" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054357/image-353.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054357/image-353-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24054357/image-353-768x703.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Wall Street's Most Accurate Analysts Spotlight On 3 Utilities Stocks With Over 5% Dividend Yields

REGN

Regeneron Launches $200M Donation Matching Program With Good Days To Expand Access To Vision-Saving Treatments In 2025

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Clean Energy Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>)</h3>
<ul class="wp-block-list">
<li>On May 23, Clean Energy Technologies announced it signed a non-binding offer with an European solar and wind development company for approximately $85 million. The company's stock fell around 20% over the past month and has a 52-week low of $0.25.</li>
<li>RSI Value: 29.9</li>
<li>CETY Price Action: Shares of Clean Energy Technologies fell 2.7% to close at $0.25 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CETY"><img loading="lazy" decoding="async" width="410" height="180" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24045338/image-349.png" alt="" class="wp-image-959378" style="width:346px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24045338/image-349.png 410w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24045338/image-349-300x132.png 300w" sizes="(max-width: 410px) 100vw, 410px" /></a></figure>
<h3 class="wp-block-heading">Black Stone Minerals LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 19, Black Stone Minerals announced that it has entered into a development agreement with Revenant Energy with respect to the Partnership&#8217;s expanded Shelby Trough Haynesville and Bossier acreage, primarily located in Angelina, Nacogdoches, and San Augustine counties in Texas. The company's stock fell around 7% over the past five days and <a href="https://www.benzinga.com/quote/BSM">has a 52-week low</a> of $12.80.</li>
<li>RSI Value: 28</li>
<li>BSM Price Action: Shares of Black Stone Minerals fell 2% to close at $12.95 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in BSM stock.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Long Ideas

CETY

Top 2 Energy Stocks Which Could Rescue Your Portfolio This Quarter

GIBO Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>), Asia's leading innovator in digital media infrastructure, today announced the successful implementation trial of its intelligent settlement and analytics engine, GIBO Click, on YouShort, a fast-rising short drama application launched in 2025. This achievement builds on the platform's growing influence across mobile-first video consumption and GIBO's broader mission to enable the next generation of creator-led platforms.
&nbsp;
The deployment of GIBO Click on YouShort enabled seamless multi-currency payment settlement and AI-powered content analytics, empowering the platform to manage viewer engagement, creator compensation and operational insights in real time. Since its inception, YouShort has rapidly scaled to over 500,000 users, 50,000 daily actives and more than 15 million cumulative views, demonstrating the accelerating global appetite for short-form entertainment.

GIBO

GIBO Powers YouShort's Creator Payments With AI and Real-Time Analytics

Today, Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) and IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) announced a collaboration to deliver on President Donald Trump's and Transportation Secretary Sean Duffy's vision for a brand new, state of-the-art air traffic control system. This collaboration directly responds to Secretary Duffy's call for world-class innovators to rapidly spearhead the overhaul of the Federal Aviation Administration's (FAA) National Airspace System (NAS), prioritizing an open vendor agnostic approach that enables the agency to leverage the latest technologies and continuously improve their systems based on real-time feedback and evolving needs. Parsons would serve as the prime contractor and single point of accountability, providing unified leadership and full program responsibility to ensure mission success.

Parsons And IBM Collaborate To Deliver On President Donald Trump's And Transportation Secretary Sean Duffy's Vision For New Air Traffic Control System

<ul>
<li>RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell carcinoma -</li>
<li>ZEVASKYN&#x2122; (prademagene zamikeracel) demonstrated significant wound healing and pain reduction after a single treatment with a favorable safety profile in large chronic RDEB wounds -</li>
<li>ZEVASKYN is the first and only autologous cell-based gene therapy FDA-approved to treat RDEB wounds in adult and pediatric patients -</li>
</ul>

ABEO

Abeona Announces Publication Of Phase 3 VIITAL Study In The Lancet Highlighting ZEVASKYN's Impact On Chronic RDEB Wounds

Asset Sales

AZEK

The AZEK Company Announces The Sale Of Scranton Products To Sky Island Capital

<a href="https://www.globenewswire.com/Tracker?data=yxUQUPouiLl0S_LFeuhGu_F13EYLaDqlRVUaNsoULublifgPWaEIfJvYZMJwNGwbwu39mW2fR8Wbu7kEeIH-egoqYAjLmb0v_rbSnQZxKIg=">Lexeo Therapeutics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Combined with investment of up to $40 million from leading life-sciences investors Perceptive Xontogeny Venture Funds ("PXV Funds") and venBio Partners ("venBio"), the partnership seeks to further revolutionize the treatment of cardiovascular diseases. The proceeds will be used to seed a new entity, the funding of which is non-dilutive to existing Lexeo shareholders.
"Delivery of DNA by adeno-associated virus has defined the first wave of genetic medicine, with potential to treat cardiovascular diseases that other modalities cannot address today. Over the next decade, however, new modalities will emerge allowing genetic medicines to treat an even broader range of cardiac diseases, and RNA therapeutics mediated by non-viral delivery are representative of this future," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "This partnership reflects an innovative approach to realize the therapeutic and economic value of promising preclinical science in a manner that benefits all stakeholders."
Under the terms of the agreement, the new entity will be focused on advancing research for novel RNA-based therapeutics via non-viral delivery for the treatment of genetically mediated cardiac conditions. Lexeo will contribute its expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform.&nbsp;&nbsp; As consideration for its contributions, at transaction close Lexeo has received a double-digit percentage equity position in the new entity and will be entitled to future milestone payments, royalties, and opt-in rights to certain program(s).

LXEO

1. Lexeo Launches $40M RNA Heart Drug Venture With Backing From Top Biotech Investors

Expands into Project Dorothy 2, Totaling 13 MW
Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced the renewal and expansion of its long-standing partnership with Compass Mining.
The expanded agreement includes a contract renewal at Soluna's Project Dorothy 1 site and a major expansion into its adjacent site, Project Dorothy 2, marking a total deployment of approximately 13 megawatts (MW) of computing capacity across the two locations.

SLNH

Soluna Holdings Announces Renewal And Expansion Of Partnership With Compass Mining

Press Releases

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Comments

Vistagen Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL